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Abstract 
Despite the application of advanced statistical and pharmacometric approaches to pediatric trial data, a 
large pediatric evidence gap still remains. Here, we discuss how to collect more data from children by using 
real-world data from electronic health records, mobile applications, wearables, and social media. The large 
datasets collected with these approaches enable, and may demand, the use of artificial intelligence and 
machine learning to allow the data to be analyzed for decision-making. Applications of this approach are 
presented, which include the prediction of future clinical complications, medical image analysis, 
identification of new pediatric endpoints and biomarkers, the prediction of treatment non-responders and 
the prediction of placebo-responders for trial enrichment. Finally, we discuss how to bring machine 
learning from science to pediatric clinical practice. We conclude that advantage should be taken of the 
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Introduction
Historically, the evidence basis of pediatric treatments has lagged behind those in adult patients. A key 
aspect of this is the lack of pediatric data, which originates from the logistic, ethical and legal challenges of 
performing clinical investigations in children.(1) Additionally, the pediatric population is more 
heterogeneous than the adult population, with maturational differences in pharmacokinetics, 
pharmacodynamics and disease etiology across the pediatric age-range from preterm neonates to 
adolescents.(1) Consequently, data collected in children within a narrow age-range might still leave us with 
limited information regarding the treatment of children outside the studied age-range. Finally, similar to 
other patient populations, optimal treatment will also differ for individuals within the same age-group for 
instance because of obesity, genetic polymorphisms or disease severity and should be improved with more 
personalized treatment approaches.(2)
To date, academic hospitals and industry perform clinical studies and randomized clinical trials (RCTs) on 
current and new drugs in children. Many academic studies focus on commonly used drugs in hospitalized 
patients, as the in-patient situation facilitates the collection of data. Generally, to minimize the study burden 
on pediatric subjects, the frequency and amount of data collection is limited and often not standardized. For 
example, to limit the number of venous samples, drug concentrations in plasma might be quantified in 
scavenged samples that were taken as part of standard of care.(3) Population pharmacometric modelling 
approaches have been successfully used to deal with these unbalanced data to better understand pediatric 
pharmacology.(1, 3) More recently, we have seen an increased use of mechanistic or physiologically-based 
models, which leverage prior knowledge regarding the physiological changes in organ weight, blood flow, 
and protein expression during a child’s life.(2, 4, 5) An important aspect of such models is their improved 
predictive performance when used to extrapolate from adults to children.(6) 
These pharmacometric modelling approaches are now, despite limited data, being used with success to 
support neonatal and pediatric drug development as well as dosing of commonly used off-label drugs.(1, 4, 
7) However, recent failures of randomized clinical trials in children have taught us that there is more to 
these studies than confirming model-based predictions.(8) These failures have been attributed to different 
reasons such as an increased placebo effect in children, different disease etiology compared to adults, and 
inadequate dose selection.(8) Another important cause is the failure to recruit sufficient patients, which can 
force investigators to costly increases of the study duration or even premature termination of a study due to 
low feasibility of recruiting the target sample size.(9, 10) Failed drug trials—and the general lack of 
pediatric clinical trials being performed particularly in primary health care—contribute to the high 
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the advances in approaches to data collection and analysis, a large need for additional research in pediatrics 
still remains.
To tackle the limitations of conventional clinical research, we need to move beyond the RCTs and their 
analysis with traditional statistical and advanced pharmacometric techniques. In this narrative review, we 
will discuss novel approaches to collecting data in pediatric patients to get more information from both 
clinical trials and real-world data. In addition, we will discuss how large datasets that are derived from new 
data collection approaches enable, and may demand, the use of innovative data science approaches such as 
machine learning. Finally, we will discuss both applications and challenges to the widespread use of 
machine learning in pediatric medicine. Together, these innovations have the potential to greatly support 
our ability to generate high quality evidence to guide optimal pediatric clinical care, thereby closing the 
pediatric evidence gap.
Advances in pediatric data collection
Improving our capacity for pediatric data collection is necessary for closing the pediatric evidence gap. 
Pediatric (randomized) clinical studies are costly and time-consuming to perform, and a sole reliance on 
these studies may limit our capacity for medical research in children. These studies are generally site-
centric, meaning that most data is collected in a hospital or physical study site. Figure 1 illustrates how the 
capacity for pediatric data collection can be increased by moving beyond site-centric pediatric studies 
towards real-world data and new techniques for patient-centric data collection.(12) Below we elaborate on 
the different opportunities and challenges (ethical and privacy) of these advances in data collection in 
pediatrics.
Real-world data collection
The collection of real-world data through electronic health records (EHRs) has sharply increased in the last 
decade, which opens up an unprecedented potential for data collection with more subjects, more variables, 
and lower costs.(13) The use of EHR data for research purposes comes with its own set of challenges, due 
to the large amount of data and variables to be analyzed. Machine learning techniques are often required to 
maximize the information extracted from EHR records. In addition to large amounts of structured data, a 
part of the information in EHR is hidden in clinical or lab notes, which complicates data analysis when this 
information is required to answer a particular question.(12) 
To extract information from such notes into structured data, techniques like natural language processing 
may provide a great opportunity for answering pediatric research questions.(14, 15) These techniques 
enable analyses that would be impossible to perform on the text data itself when it would be too time-
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natural language processing was used to automatically notate whether a certain condition or finding is 
mentioned within the text of the report.(16) In another example, Liang and others used natural language 
processing to allow the use of unstructured information from EHR for the development of a deep learning 
model for automatic pediatric diagnoses that surpassed the accuracy of junior, but not senior, 
physicians.(17) Finally, the data extracted using natural language processing might be required to identify 
patients eligible for inclusion in cohorts for observational research.(15)
While effectiveness research with real-world data can be problematic due to the difficulty in controlling for 
confounding variables and non-randomized treatment decisions, real-world data offer many other 
opportunities.(12, 18, 19) First, real-world data might be used to generate or select hypotheses on the most 
effective treatment that can then be tested in a RCT. Alternatively, real-world data might be used to 
confirm that the findings in a well-controlled RCT also apply to the wider, more heterogeneous pediatric 
population or establish that some subpopulations require additional research.(18) Additionally, real-world 
data can also be used to better characterize patients outside clinical studies as natural history cohorts which 
can subsequently be used as an external control to replace placebo arms in pediatric trials.(19) While 
externally-controlled studies require additional considerations to deal with potential biases compared to 
traditional RCTs, this approach might provide an opportunity for performing studies in cases where 
sufficiently powered RCTs are difficult to perform due to rarity of the indication or reluctance of parents to 
consent to a placebo-controlled trial.(19-21) Finally, real-world data may be more suitable than RCTs for 
answering drug safety questions regarding rare adverse effects or adverse effects that present themselves 
years after the initial drug exposure.(18, 22)
To deliver the best medical practice tomorrow, it is important that we harness the full potential of the data 
collected today. At the moment, data in EHR is still primarily collected for medical practice, and may 
sometimes be ill-suited for secondary use as research data. This is compounded by the fact that physicians 
are primarily responsible for treating patients and not for generating high-quality research data.(18) In a 
learning healthcare system, real-world data are not only collected to treat the individual patient, but also 
readily usable to improve clinical practice by contributing to the generation of knowledge and 
innovations.(18, 23) Examples of initiatives include the PEDSnet learning healthcare system, a large 
clinical data research network that currently holds data of over six million children from 2009 onwards and 
has enabled the generating of real-world evidence in a variety of clinical settings, including obesity, 
leukemia and long-term safety of (maternal) drug use.(24) Also important are initiatives like the European 
EHR4CR project(25) that support the integration of data from different EHR systems, as this allows the 
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Patient-centric data collection
In addition to data from site-centric RCTs, in which most data is collected in one or more physical study 
sites(22), the collection of patient-centric data has the potential to increase the capacity for data collection 
(Figure 1).(22, 23) Patient-centric data refers to data collected from the patient at home or during other 
parts of their daily routine. Depending on the context, data could be collected using mobile applications, 
wearables and social media. A specific advantage of patient-centric data is the increase of study data 
without increasing the study burden associated with additional study visits that may in the case of children 
affect their parents or caregivers as well. The opportunities of patient-centric data collection are particularly 
important for studying chronic diseases in children that do not require hospitalization or frequent hospital 
check-ups as part of their treatment. Another potential application would be the long-term follow-up of 
previously hospitalized patients.
Mobile applications
In its simplest form, a mobile application might be an electronic diary, designed to collect self-reported 
outcomes which can be reported by children when they are beyond a certain age or by the parents in case of 
younger children. Compared to a paper diary, electronic diaries are reported to improve compliance with 
alerts, and to reduce the risk of errors during data entry.(26) In other cases, the primary aim of the 
application is to promote healthy behavior in the child through motivation or education, for example in 
applications that help older children with self-management of asthma or type 1 diabetes.(27) The 
interactions by the child and/or their parents with these applications may offer great opportunities for data 
collection.
Wearables
The use of wearables creates the possibility of continuous data collection in an at-home setting, which 
supports characterizing the intra- and inter-individual variability in disease and drug response, as well as 
quantifying exposure-response relationships for drugs in the pediatric population.(28) The latter is 
especially true if the clinical outcome or a surrogate endpoint can be quantified at home. Similar to mobile 
applications, the wearable itself might not only be used to collect data, but also to motivate desirable 
behavior. For example, Hooke et al. evaluate the use of activity trackers to promote physical activity in 
children with acute lymphoblastic leukemia in an effort to reduce treatment-induced fatigue.(29)
Wearables can also include biochemical sensors to non-invasively measure electrolytes, metabolites and 
proteins in an at-home setting. Wearables worn on the skin can be used to measure analytes directly in 
sweat, but can also non-invasively extract analytes such as proteins and glucose from the skin’s interstitial 
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developments in this area will likely expand the applicability of these techniques for patient-centric 
collection of pediatric biochemical data.
While these wearables may provide great opportunities for data collection in otherwise difficult to study 
patient populations like children, it is important to note that the field of clinical application of wearables is 
still in its infancy when we consider its clinical utility, even for adult patients.(31) There are a variety of 
challenges that need to be met in scientific, logistic, ethical and privacy aspects, as covered extensively by a 
recent review by Izmailova et al.(26) For example, commercially available wearables frequently do not 
report the raw data, but only the summary or secondary data that has been processed with undisclosed and 
proprietary algorithms. This complicates the interpretation of wearable data, especially when collecting 
data from multiple types of wearables with differing terminology and data standards. For the pediatric 
application of wearables, additional validation will be required to ensure devices are also fit-for-purpose for 
children of a particular age-group, and whether the data measured with these devices have the same 
relevance for the clinical outcome. Finally, the use of wearables by study participants might affect their 
behavior (e.g. they might walk more when wearing a wearable that tracks their daily step count), which 
could be a problem depending on the research question and design of the study. Despite these challenges, 
their ability for continuous data collection at low burden to the patient could provide a great opportunity in 
the effort to fill the pediatric evidence gap, especially if the link can be made to clinical outcomes and 
biomarkers.
Social media data
The use of social media has increased dramatically over the last decade. It has been reported that children 
that use medication might use these platforms to share experiences that are not communicated to their 
healthcare practitioner.(32) As such, social media might contain information useful to pediatric 
pharmacovigilance that is not available elsewhere. Recent studies explored patient reports of adverse 
effects on social media platforms such as Twitter(33) and patient fora.(34) This information was explored 
by counting how many times different adverse effects were mentioned in combination with a certain drug. 
These studies could serve as a method for signal detection of rare adverse effects, or to supplement 
information on known adverse effects that are underestimated in children. 
At the moment, the use of social media data for pharmacovigilance is still in its infancy. In a recent study 
from the IMI project WEB-RADR, natural language processing techniques that were used to automatically 
label social media posts with drugs and adverse effects combinations were only correct in about 40% of the 
cases.(35) Using these imprecise techniques, the authors found no indication that posts on general social 
media platforms like Facebook and Twitter would have an added value to traditional methods of 
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discussed in social media posts, thus having little to no potential for advancing pharmacovigilance.(35) The 
use of social media posts in pharmacovigilance might be more beneficial with further advances in natural 
language processing and by directing research efforts towards patient fora which would carry a higher 
percentage of relevant posts than general social media platforms.
Ethical and privacy aspects of pediatric data collection
Innovations in data collection will support our ability to effectively treat pediatric patients in the future, 
especially when the collected data is FAIR (Findable, Accessible, Interoperable, Reusable) to allow 
secondary analyses to be performed by the broader research community. These benefits need to be balanced 
with the right to privacy of the patients whose data is used in this research. Maintaining and further 
developing ethical and data security standards are crucial to ensure ongoing support by patients and their 
parents of data collection for research purposes.(36) Maintaining data security is particularly challenging 
for patient-centric data collection where sensitive data are collected on a mobile phone or wearable, as data 
leaks could occur when the device is lost or during data transfer from the device to the central database.
Appropriate security measures need to be in place to minimize the risk of violating the patient’s privacy. In 
this respect, the removal of identifying information can contribute to maintain privacy when using data for 
research purposes. However, when the research question requires that data from different databases are 
linked, some form of patient identifier might be needed to do this.(37) A potential solution to this issue is to 
add a small amount of noise to the data to ensure patients cannot be identified.(37) Another interesting 
approach is to ‘share the answers, not the data’. In this case, a data analysis or model might be run on the 
data, and only the aggregated results are returned to the researchers.
The issue of consent is particularly complex for pediatrics. Depending on the age of the child, (written) 
informed consent might be obtained from the parents, the child or both. However, in the case of re-use of 
the data, there are questions that remain unanswered.(38) Can the parental informed consent be considered 
to be valid for re-use of the data years later, even if the patient has since reached adolescence or adulthood? 
It is recognized that retrospectively obtaining informed consent for large datasets of observational real-
world data could likely result in lengthy and costly procedures, which would limit their use in practice.(37) 
However, for some observational analyses of de-identified data, the need for informed consent can be 
waived by institutional review board, if appropriate privacy measures are taken.(37)
Machine Learning for evidence generation
Innovations in pediatric data collections provide great opportunities for research and hold great promise in 
closing the pediatric evidence gap, but this promise can only be fulfilled if these data are used effectively to 
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collected with these novel techniques. Collecting new types of data will therefore go hand in hand with the 
increasing use of artificial intelligence and machine learning in pediatrics.
The term machine learning is often used interchangeably with the term artificial intelligence (AI).AI is an 
area in the discipline of computer science that aims to create intelligently perceiving, reasoning, and acting 
machines. A subset of AI is machine learning, which encompasses a wide range of advanced data analysis 
techniques. Depending on techniques used, machine learning algorithms can predict both numerical 
outcomes (e.g. a disease severity score) or class labels (e.g. healthy versus diseased). 
With respect to the different classes of machine learning techniques, linear models are an easy to interpret 
class of machine learning techniques for the analysis of structured data (Figure 2). Linear regression, which 
is the most common linear modelling technique, can be used for both prediction and hypothesis testing, but 
is not suitable when there are many variables in the dataset. In those cases, penalized regression techniques 
can be used, which have a penalty term to constrain overfitting. Examples of such techniques include 
LASSO(39) and ridge regression.(40) A second class of machine learning techniques are tree-based models, 
such as Classification And Regression Trees(41) and random forests.(42) Depending on specific type of 
technique, the output of a tree-based model might be a form of a decision tree, which can still be relatively 
well explained. A third class of machine learning techniques is deep learning or deep neural networks. 
Deep learning has been used extensively for image analysis and text mining outside the medical world, and 
has recently started to be used on medical images and electronic health records (Figure 2).(43) Complex 
deep learning models can have a good predictive performance when dealing with unstructured data due to 
flexibility of such models (Figure 2). However, deep learning models are often difficult to explain, as it is 
generally difficult to understand how the input data leads to the model prediction. 
Of note, it is important to recognize that machine learning will supplement, and not replace, traditional 
statistics in pediatric research. The use of traditional statistical tests or linear models might be more 
appropriate if the primary goal of the analysis is not to obtain a prediction model.(44, 45) This includes 
situations when the goal of the analysis is hypothesis testing (‘Does the treatment work better than 
placebo?’) or estimation of treatment effect (‘What effect does the treatment have on the outcome?’). 
However, there are various clinical problems in which the predictions made by machine learning can 
contribute to closing the pediatric evidence gap, as will be illustrated with examples in the next section.
Applications of machine learning in pediatrics
The opportunities offered by the various machine learning techniques can benefit pediatric practice in a 
variety of ways. In this section, we will discuss different applications of machine learning in pediatrics 
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pediatric endpoints and biomarkers, prediction of treatment non-responders, and the prediction of placebo-
responders to allow pediatric trial enrichment. 
Predicting future clinical complications
The ability to predict clinical complications in the future can be used to deliver more personalized medicine 
in pediatrics. For this purpose, machine learning plays a crucial role due to its improved potential predictive 
performance compared to traditional statistical methods, especially when the data are unstructured or 
otherwise complex. Children that are predicted to be at high risk for a certain event, can subsequently be 
monitored and treated more intensively. In recent research, new algorithms have been explored to make 
good predictions using data from previous studies or real-world data. Box 1 shows three case studies in 
which machine learning techniques were used to make predictions about future clinical complications such 
as childhood obesity(46), late onset sepsis(47) and neonatal hyperbilirubinemia(48). 
Box 1. Prediction of clinical complications in pediatrics using machine learning 
Case study 1. Childhood obesity
Dugan et al. (2015) explored predictors of childhood obesity, with the aim of eventually being able to 
provide targeted obesity prevention for high-risk children. The answers on a dynamic questionnaire 
and measurements of clinical staff were mined from over 7000 children below the age of 2 years. 
These features were used to predict the prevalence of obesity after their second birthday. Using tree-
based machine learning, an accurate model predicting childhood obesity was obtained, which 
included predictors like pre-existing obesity, ethnicity, height and maternal depression. 
Case study 2. Neonatal sepsis
Mani et al. (2014) evaluated the usefulness of different classification algorithms to predict late onset 
sepsis in neonates, using early results of laboratory tests and nursing observations. The best 
classification algorithm surpassed the clinician in both the sensitivity and specificity of predicting 
neonatal sepsis. After validation, clinical implementation could allow earlier treatment of sepsis while 
reducing the number of patients unnecessarily treated with antibiotics.
Case study 3. Neonatal hyperbilirubinemia
Daunhawer et al. (2019) used machine learning techniques to predict neonatal hyperbilirubinemia. An 
ensemble classifier combining the logistic regression LASSO and random forests was able to predict 
accurately whether a neonate would undergo phototherapy treatment in the next 48 hours. The 
predictions were made using clinical variables, such as birth weight and health information about the 
mother. This model could support a more personalized bilirubin monitoring approach, with more 
intensive monitoring of high-risk patients.
Medical image analysis
Deep learning models have been particularly effective in image analysis, mainly in radiology.(49) A deep 
learning model can learn to classify images as healthy or diseased, or can notate the areas in the image that 
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identify the segmentation of white matter, grey matter and cerebrospinal fluid in the brains of babies.(50) 
The automation of these tasks with a deep learning model can reduce the time spent on an image by 
limiting the radiologist’s task to checking and adjusting the lines drawn by the algorithm. In another 
example, a deep learning model was able to identify the skeletal maturity of children by assessing hand 
radiographs.(51) Another common application is the detection of malignant tumors in medical images, 
which could serve as a second opinion to detect malignancies that might have been missed by the 
radiologist.(52, 53)
In addition to increasing efficiency, deep learning models could also extract information from image data 
that is not included in the radiologist report. This would include features that are too complex and time-
consuming to extract manually or features that are not currently being used in clinical decision making.(54) 
With automated extraction of additional information from medical images, deep learning-based image 
analysis can be used to perform research on imaging-based pediatric biomarkers that would not be feasible 
with manual image analysis.
Identifying endpoints and biomarkers in pediatrics
The development and validation of pharmacodynamic endpoints for children is recognized as an important 
methodological step in closing the evidence gap of pediatric medicine.(55) Having suitable disease-specific 
pharmacodynamic endpoints for children is essential for demonstrating efficacy and for establishing the 
exposure-response relationship of drugs needed for pediatric drug labeling. Additionally, these measures of 
patient disease severity or well-being can guide treatment decisions in clinical practice. For this, the 
efficacy and safety endpoints used in adults may not be fit-for-purpose across the pediatric age-range: the 
clinical endpoint might not occur until later in life, might not be directly measurable, or the clinical 
presentation of the disease might differ too much from any adult counterpart.(55) 
Machine learning can be used in biomarker and endpoint discovery by performing variable selection and 
dimension-reduction when there are multiple variables considered to be potentially relevant for pediatric 
outcome. For example, Hartley et al. used EEG data to derive a summary measure for nociceptive brain 
activity in infants.(56) In this example, the EEG-based measure of pain was learned from the context, i.e. 
by comparing the response profiles after non-noxious or noxious stimulation. In another example, a 
supervised learning approach was used to derive a measure of iatrogenic withdrawal severity in children by 
combined analysis of nurse’s expert opinion of the child’s withdrawal severity, and the observed 
withdrawal symptoms.(57) Finally, machine learning may be used to identify early biomarkers that 
correspond to long-term clinical endpoints or quality-of-life.(58) For example, a machine learning tool is 
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Predicting treatment responders
Machine learning techniques can also be used to identify non-responders, i.e. children that are unlikely to 
respond to a particular treatment. The clinical benefit lies in avoiding therapy that might give adverse 
effects at low chance of beneficial effects, as well as reducing the need for trial-and-error approaches for 
treatment personalization.(60)
For the adults, machine learning techniques have been used to predict non-responders to drug treatment in 
different settings, including oncology, immunology, and postoperative pain.(60-62) Depending on the 
similarity of disease between adults and children, and the explicability and the biological plausibility of the 
machine learning model, models developed in adults might be also applicable in the pediatric setting after 
validation. In other cases, the pediatric pathophysiology might be too different or the disease might be 
absent in adults. In this case, efforts would be warranted to develop new machine learning models to 
predict drug response in children, so that they can also benefit from these innovations. 
Predicting placebo responders to improve trial success
Prospective (randomized) clinical trials remain the gold standard to get drugs registered for the pediatric 
population. However, some of these RCTs fail to demonstrate efficacy in children.(8) These failures have 
been attributed to a numbers of reasons, one of which is the high placebo response observed in indications 
such as depression, migraine, and bipolar disorder.(8) A high placebo response would limit the ability of a 
trial to demonstrate efficacy or would require a very large sample size to do so. Additionally, it has been 
shown that younger children tend to have a stronger placebo response than older children.(63) This would 
make it especially difficult to demonstrate efficacy in younger children, which is problematic considering 
that the off-label drug use is highest in children in the first year of life.(11) 
One way to limit the impact of placebo response on trial outcomes, would be to identify baseline predictors 
of placebo response so that trials can be enriched pre-randomization with subjects that are less likely to 
respond strongly to placebo.(8) This strategy has been used in pediatric trials, resulting for example in the 
successful application for a pediatric indication of rizatriptan for acute treatment of migraine.(64) For 
adults, it has been proposed machine learning techniques may have better predictive power when using 
multiple variables to predict placebo response, as was demonstrated for depression in a geriatric 
population.(65) The use of machine learning techniques to reduce the placebo response in pediatric trials, 
might therefore increase the success rate of pediatric drug trials and support pediatric drug labeling.
Bringing machine learning to pediatric practice
While promising, more work needs to be done before the machine learning applications mentioned in the 
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need to be developed for different therapeutic indications, and prove their worth in practice by increasing 
the success of pediatric registration trials (Figure 3, left column). Biomarkers and endpoints suggested by 
machine learning need to be validated, and supported by the relevant stakeholders (Figure 3, middle 
column). When this is the case, having better pediatric endpoints and biomarkers will impact not only 
pediatric practice, but also pediatric research. Considerable work is also required to bring a machine 
learning model to the clinic as a medical decision support tool, as this requires extensive external validation 
of the model, the development of a user-friendly software tool, and assessment of the impact of the use of 
this tool in clinical practice (Figure 3, right column). Below, we will discuss the issue of validation of 
machine learning models for clinical use, and the particular challenges of implementing medical decision 
support tools in pediatric clinical practice.
Validation for clinical use in pediatrics
Machine learning models enable us to use complex data to achieve improved predictions of health and 
disease in children compared with traditional methods. However, it is important that the trained model does 
not “overfit” the data. An overfitted machine learning model has good predictive performance in the dataset 
it was trained on, but poor performance when predicting for new cases. Validation of the model on an 
independent test data set is therefore essential to ensure the scientific quality and the clinical utility of the 
model (Figure 3, right column). Obtaining suitable datasets for this external validation can be challenging, 
especially in pediatric research, which underlines the importance of efforts to promote data sharing and the 
use of real-world data for research purposes.(66)
Considering the heterogeneity of the pediatric population aged 0 to 18 years, it is also important to consider 
that a model might have a good predictive performance for children in a particular age-group, but a poor 
performance for others (e.g. preterm neonates vs term neonates). This risk is particularly high if certain 
age-groups are underrepresented or absent in the dataset used to develop the model.(67) Transparency 
about the validity of the model, and for which pediatric population this validity has been shown, is 
therefore crucial.
Finally, it is important to recognize that even externally-validated model predictions are not guaranteed to 
improve patient outcome when used in clinical practice. Some have therefore proposed that the clinical use 
of models as medical decision support tools should supported by studies that demonstrate their impact on 
relevant clinical endpoints (Figure 3, right column).(68) Considering the added difficulty to perform such 
trials in children, we argue that it is important to consider the need for such trials on a case-by-case basis, 
depending on the potential risk and benefits of the use (and non-use) of machine learning tools in clinical 









This article is protected by copyright. All rights reserved
workflows used in pharmacometrics might be used to assess the likely clinical benefit-risk ratio of decision 
support tools by integrating available data from adult and pediatric patients.(69)
Implementation of medical decision support tools
Implementation of findings from machine learning studies into pediatric clinical practice will not happen 
without focused efforts and close involvement of the various stakeholders. Currently, the widespread 
clinical implementation of scientific evidence is a lengthy process (>15 years on average) and only 
achieved in about half of the cases.(70) Wittmeier and colleagues have argued in favor of systematic step-
wise approaches to bring scientific knowledge to pediatric clinical practice. An important aspect of this is 
to engage in activities that have been shown to successfully support implementation, such as educational 
outreach and meetings, use of local opinion leaders, computerized reminders, audit and feedback.(71) For 
the implementation of machine learning as a medical decision support tool in pediatrics, there are additional 
challenges to overcome (Figure 3, right column).(36)
Because the predictions or classifications of machine learning tools can incorporate information of multiple 
variables, they are not as readily integrated in clinical guidelines as knowledge that relies on a single 
variable (e.g. age or bodyweight) for decision making. Therefore, software packages might be needed so 
that physicians can easily use models in medical decision making (Figure 3, right column). It is important 
to stress that such software packages should be quick and simple to use, and ideally linked to the EHR 
system so that there is no need for error-prone data entry of a large number of variables by the clinician. 
The need to integrate machine learning tools into software packages does complicate their implementation, 
as they can be classified by the FDA as a medical device if the physician is not able to independently 
evaluate the basis of the recommendation.(72) With complex machine learning models, this is likely the 
case. Many software packages that provide recommendations based on models obtained with machine 
learning would therefore require lengthy regulatory approval procedures before they can be used in clinical 
practice.  
In addition, to being easy to use, the advice of the model should be explicable by the clinician. Here, lies a 
key challenge for machine learning tools, especially for techniques like neural networks which provide 
more ‘black box’ predictions.(73) The integration of such ‘black box’ predictions in clinical decision 
making is problematic, because it means a departure from the paradigm of evidence-based medicine.(74) 
Additionally, shared decision making between the patient and physician also requires that decisions 
supported by machine learning tools can also be explained.(67, 73) Therefore, explicability for both the 
physician and the patient is likely a requirement for meaningful contributions to the decision process. 
Ongoing efforts to improve the explicability of complex machine learning models are therefore crucial to 
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Conclusions
Innovations in data collection and analysis could revolutionize many aspects of medical science and clinical 
practice in the upcoming decades. With the increased use of real-world data within a learning healthcare 
system and patient-centric data collection there is a potential to significantly expand our capacity for 
pediatric data collection. There are many useful potential applications of the predictive performance of 
machine learning models, and future work may integrate these applications with mechanistic modelling to 
improve understanding of the underlying biology. And even though efforts are required to bring these 
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Figure legends
Figure 1. Innovative pediatric data collection beyond the site-centric randomized clinical trial 
(RCT). Data from these pediatric clinical studies can be supplemented by increased use of real-
world pediatric data from electronic health records. Additional information can be obtained 
without increasing patient burden by using patient-centric data collection tools, such as mobile 
applications, wearables and social media data. Site-centric RCTs refer to studies in which data 
collection is limited to one or more hospitals or physical study sites. Patient-centric data refers to 
data collected from the patient at home or during other parts of their daily routine. 
Figure 2. Explicability of the various machine learning techniques. On the far left, linear models 
have a clear explanation, but require that the data is structured. Linear regression, the most 
common linear modelling technique, can be used for both prediction and hypothesis testing, but is 
not suitable when there are many variables in the dataset. On the opposite end of the spectrum, 
deep learning models are generally difficult to interpret and explain, and not suitable for 
hypothesis testing. However, due to the flexibility of deep learning models, they are able to handle 
complex and unstructured data such as image and text data. Depending on the data (structured or 
unstructured) and the goal of the analysis (raw predictive performance or testing hypotheses), 
different techniques will be most appropriate.
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